Physician profile
Tracy A Onal
NPI 1508962002
$8,181.22
in general payments reported to CMS, 2019-2025
41 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Neuromusculoskeletal Medicine, Sports Medicine provider received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $865 · 2020: $800 · 2021: $1,928 · 2022: $1,948 · 2023: $1,808 · 2024: $507 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,590 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,590.23 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $920.35 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Astrazeneca Pharmaceuticals Lp | $892.67 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $781.93 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $773.78 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $747.34 | 2021-2025 | |
| Pfizer INC. | $649.60 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $524.27 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amarin Pharma, INC. | $352.30 | 2019-2022 | |
| Daiichi Sankyo INC. | $301.78 | 2020-2023 | Injectafer |
| Janssen Pharmaceuticals, INC | $256.91 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $207.91 | 2019-2023 | Belsomra |
| Otsuka America Pharmaceutical, INC. | $184.95 | 2021-2023 | Rexulti |
| Esperion Therapeutics, INC. | $157.45 | 2021-2025 | Nexletol |
| Boston Scientific Corporation | $148.41 | 2023 | |
| Amgen INC. | $140.08 | 2019-2023 | Otezla, Repatha |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $124.97 | 2019-2024 | Freestyle Libre 3 |
| Currax Pharmaceuticals LLC | $111.67 | 2021-2023 | Nexletol, Contrave, Nexlizet |
| Kowa Pharmaceuticals America, INC. | $105.52 | 2020-2023 | Seglentis |
| Exact Sciences Corporation | $97.51 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $82.65 | 2022-2023 | Quviviq |
| Allergan, INC. | $67.84 | 2020 | |
| Bausch Health US, LLC | $54.86 | 2021-2025 | Aplenzin |
| Genentech USA, INC. | $48.17 | 2019 | |
| Shield Therapeutics INC | $44.64 | 2023-2024 | Accrufer |
| Intra-Sana Laboratories | $43.28 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Lundbeck LLC | $37.87 | 2022-2023 | Rexulti |
| Medicomp INC | $30.33 | 2025 | Telepatch Cardiac Monitor |
| Biohaven Pharmaceuticals, INC. | $29.46 | 2021 | |
| Corcept Therapeutics | $26.37 | 2024 | Korlym |
| Axsome Therapeutics, INC. | $26.14 | 2025 | Auvelity |
| Sumitomo Pharma America, INC. | $24.96 | 2025 | Gemtesa |
| Astellas Pharma US INC | $22.85 | 2023 | Veozah |
| Smith+Nephew, INC. | $21.57 | 2024 | Collagenase Santyl |
| Renalytix Ai, INC. | $21.23 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Avvisto Therapeutics, LLC | $19.89 | 2024 | Cycloset |
| Arbor Pharmaceuticals, INC. | $18.50 | 2019 | |
| Evoke Pharma, INC. | $17.93 | 2022 | |
| Sanofi Pasteur INC. | $16.83 | 2020 | |
| Averitas Pharma INC. | $16.60 | 2025 | Qutenza |
| Qiagen, LLC | $15.45 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $14.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Onal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.